Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
Genelux (NASDAQ: GNLX) announced its participation in the Guggenheim Inaugural Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. CEO Thomas Zindrick will engage in a fireside chat on November 11 at 1:30 p.m. ET with Brittany Stopa, Biotech Equity Research Analyst at Guggenheim, discussing clinical-stage programs, recent announcements, and upcoming milestones.
The event will be accessible via webcast, with a replay available for 90 days on the company's IR page. Genelux management will also be available for one-on-one meetings during the conference, with institutional investors invited to register or contact the company directly.
Genelux (NASDAQ: GNLX) ha annunciato la sua partecipazione alla Guggenheim Inaugural Healthcare Innovation Conference a Boston, Massachusetts, dal 11 al 13 novembre 2024. Il CEO Thomas Zindrick prenderà parte a una chiacchierata informale il 11 novembre alle 13:30 ET con Brittany Stopa, Analista di Ricerca sulle Azioni Biotech presso Guggenheim, per discutere dei programmi in fase clinica, degli annunci recenti e dei traguardi futuri.
L'evento sarà accessibile tramite webcast, con una registrazione disponibile per 90 giorni sulla pagina IR della società. Il management di Genelux sarà inoltre disponibile per incontri individuali durante la conferenza, con inviti per gli investitori istituzionali a registrarsi o contattare direttamente l'azienda.
Genelux (NASDAQ: GNLX) anunció su participación en la Guggenheim Inaugural Healthcare Innovation Conference en Boston, Massachusetts, del 11 al 13 de noviembre de 2024. El CEO Thomas Zindrick participará en una charla informal el 11 de noviembre a la 1:30 p.m. ET con Brittany Stopa, Analista de Investigación de Equidades Biotech en Guggenheim, discutiendo los programas en etapa clínica, anuncios recientes y hitos por venir.
El evento será accesible a través de un webcast, con una repetición disponible durante 90 días en la página de IR de la empresa. La dirección de Genelux también estará disponible para reuniones individuales durante la conferencia, invitando a los inversores institucionales a registrarse o contactar a la empresa directamente.
Genelux (NASDAQ: GNLX)는 2024년 11월 11일부터 13일까지 매사추세츠주 보스턴에서 열리는 구겐하임 의료 혁신 컨퍼런스에 참여한다고 발표했습니다. CEO 토마스 진드릭은 11일 오후 1시 30분(ET)에 구겐하임의 바이오텍 주식 연구 분석가인 브리타니 스토파와 함께 임상 단계 프로그램, 최근 발표 및 다가오는 이정표에 대해 이야기하는 라운드 테이블에 참여할 예정입니다.
이 행사는 웹캐스트를 통해 접근 가능하며, 회사의 IR 페이지에서 90일 동안 재생할 수 있습니다. Genelux 경영진은 또한 회의 동안 개인 미팅이 가능하며, 기관 투자자들은 등록하거나 회사에 직접 연락할 수 있도록 초대받고 있습니다.
Genelux (NASDAQ: GNLX) a annoncé sa participation à la Guggenheim Inaugural Healthcare Innovation Conference à Boston, Massachusetts, du 11 au 13 novembre 2024. Le CEO Thomas Zindrick participera à une conversation informelle le 11 novembre à 13h30 ET avec Brittany Stopa, Analyste en Recherche d'Actions Biotech chez Guggenheim, pour discuter des programmes en phase clinique, des annonces récentes et des jalons à venir.
L'événement sera accessible via un webinaire, avec un replay disponible pendant 90 jours sur la page IR de l'entreprise. La direction de Genelux sera également disponible pour des réunions individuelles pendant la conférence, invitant les investisseurs institutionnels à s'inscrire ou à contacter directement l'entreprise.
Genelux (NASDAQ: GNLX) gab seine Teilnahme an der Guggenheim Inaugural Healthcare Innovation Conference in Boston, Massachusetts, vom 11. bis 13. November 2024 bekannt. CEO Thomas Zindrick wird am 11. November um 13:30 Uhr ET an einem informellen Gespräch mit Brittany Stopa, Biotech-Aktienanalystin bei Guggenheim, teilnehmen, um über Programme in der klinischen Phase, jüngste Ankündigungen und bevorstehende Meilensteine zu sprechen.
Die Veranstaltung wird über einen Webcast zugänglich sein, mit einer Wiederholung, die für 90 Tage auf der IR-Seite des Unternehmens verfügbar ist. Das Management von Genelux wird während der Konferenz auch für persönliche Gespräche zur Verfügung stehen, wobei institutionelle Investoren eingeladen sind, sich zu registrieren oder direkt mit dem Unternehmen in Kontakt zu treten.
- None.
- None.
WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference, taking place November 11-13, 2024, in Boston, Massachusetts.
The conversation with Brittany Stopa, MD, Biotech Equity Research Analyst at Guggenheim, is scheduled to begin at 1:30 p.m. ET on Monday, November 11, 2024. A webcast link for the Guggenheim Conference event will be available at https://wsw.com/webcast/guggen/gnlx/1958805. An archived replay will be available for approximately 90 days following the event on the company’s IR page.
The Company will also attend one-on-one meetings during the conference. Institutional investors interested in arranging a meeting with Genelux management can register to attend the conference or contact genelux@allelecomms.com.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its’ proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
FAQ
When is Genelux (GNLX) presenting at the Guggenheim Healthcare Conference 2024?
How can investors watch Genelux's (GNLX) Guggenheim Conference presentation?
How can institutional investors meet with Genelux (GNLX) management at the Guggenheim Conference?
